PTGX

Peers: ORKA INCY IRON ALMS KYMR SLN MLTX SYRE JNJ TAK

| Held by: IJR VTI IWM VB XBI VBK VXF IJT SPSM IWO

Index	RUT
Market Cap	8.96B
Enterprise Value	8.18B
Income	82.91M
Sales	281.99M
Book/sh	13.01
Cash/sh	12.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	132
IPO	Aug 11, 2016

P/E	133.48
Forward P/E	-
PEG	-
P/S	31.77
P/B	10.64
P/C	11.45
P/FCF	68.60
EV/EBITDA	136.68
EV/Sales	29.02
Quick Ratio	21.71
Current Ratio	21.71
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	1.04
EPS next Y	-0.39
EPS next Q	2.50
EPS this Y	328.98%
EPS next Y	-108.29%
EPS next 5Y	-
EPS past 3/5Y	7.63% -1.26%
Sales past 3/5Y	20.07% 9.96%
EPS Y/Y TTM	44.59%
Sales Y/Y TTM	34.81%
EPS Q/Q	518.89%
Sales Q/Q	3749.17%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	3.46% 7.46%

Insider Own	5.39%
Insider Trans	-11.31%
Inst Own	114.70%
Inst Trans	-4.21%
ROA	10.34%
ROE	10.98%
ROIC	9.77%
Gross Margin	99.45%
Oper. Margin	20.69%
Profit Margin	29.40%
SMA20	-0.30%
SMA50	-3.78%
SMA200	19.97%
Trades

Shs Outstand	64.67M
Shs Float	61.22M
Short Float	15.27%
Short Ratio	14.72
Short Interest	9.35M
52W High	160.81 -13.92%
52W Low	73.83 87.49%
Volatility	4.07% 4.06%
ATR (14)	5.25
RSI (14)	47.90
Beta	1.21
Rel Volume	0.01
Avg Volume	634.75K
Volume	369

Perf Week	2.97%
Perf Month	-2.42%
Perf Quarter	1.16%
Perf Half Y	40.52%
Perf YTD	58.50%
Perf Year	84.92%
Perf 3Y	874.17%
Perf 5Y	326.99%
Perf 10Y	527.52%
Recom	1.07
Target Price	178.20
Prev Close	138.43
Price	138.43
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-12-26	Initiated	UBS	Buy	$184
Aug-10-26	Upgrade	Goldman	Neutral → Buy	$186
May-21-26	Initiated	Wolfe Research	Outperform	$135
Sep-17-25	Initiated	Barclays	Overweight	$72
Sep-12-25	Initiated	Leerink Partners	Outperform	$73
Jun-17-25	Initiated	Citigroup	Buy	$72
Dec-06-24	Initiated	Goldman	Neutral	$47
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$62
Nov-05-24	Initiated	Wedbush	Outperform	$58
Sep-24-24	Initiated	TD Cowen	Buy	$65
Sep-09-24	Initiated	Truist	Buy	$60
Oct-30-23	Initiated	CapitalOne	Overweight	$32
May-25-23	Resumed	Jefferies	Buy	$30 → $40
Aug-25-22	Initiated	JMP Securities	Mkt Outperform	$21
Feb-11-22	Initiated	BTIG Research	Buy	$55
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight	$49 → $55
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform	$40
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral	$60 → $49
May-24-21	Initiated	Northland Capital	Outperform	$42
May-24-21	Initiated	JMP Securities	Mkt Outperform	$48

Show Previous Ratings

Oct-20-26 08:59AM	A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday (PR Newswire)
Sep-25-26 05:30AM	The Peptide Boom That Isn't About Your Muscles (The Wall Street Journal)
Sep-08-26 04:05PM	Protagonist Therapeutics Announces $300 Million Share Repurchase Program (ACCESSWIRE)
Sep-02-26 07:05AM	Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 (ACCESSWIRE)
Aug-31-26 08:13AM	FDA OKs Takeda, Protagonist drug for rare blood cancer (BioPharma Dive)
08:30PM	Loading…
Aug-28-26 08:30PM	Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera (ACCESSWIRE)
Aug-18-26 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Aug-12-26 05:11AM	Silence cashes in on differentiated data; UK reaffirms support for childhood vaccines (BioPharma Dive)
Aug-05-26 04:25PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press) +6.45%
04:05PM	Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-04-26 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Jul-16-26 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE) +6.73%
Jul-01-26 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE) +5.15%
Jun-16-26 04:00PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Jun-01-26 07:05AM	Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress (ACCESSWIRE)
07:05AM	Loading…
May-28-26 07:05AM	Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026 (ACCESSWIRE)
05:30AM	J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge? (The Wall Street Journal)
May-06-26 03:11AM	Protagonist Therapeutics: Q1 Earnings Snapshot (Associated Press)
May-05-26 04:05PM	Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-28-26 09:05AM	Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration (ACCESSWIRE)
Apr-16-26 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Apr-14-26 06:55AM	J&J raises guidance for 2026 on strong start to the year (MarketWatch) +7.33%
Mar-28-26 10:05AM	Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting (ACCESSWIRE)
Mar-25-26 01:10PM	Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets (Barrons.com)
Mar-18-26 08:05AM	Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis (ACCESSWIRE)
Mar-02-26 02:00AM	Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera (Business Wire)
Feb-25-26 06:15PM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
05:15PM	CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
04:05PM	Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-24-26 07:30AM	Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026 (ACCESSWIRE)
03:13PM	Loading…
Feb-11-26 03:13PM	H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy (Insider Monkey)
Jan-07-26 07:30AM	Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 (ACCESSWIRE)
Jan-06-26 04:29PM	Alumis Stock Catapults More Than 95% As Biotech Takes On J&J, Protagonist In Psoriasis (Investor's Business Daily)
07:05AM	Takeda and Protagonist seek FDA approval for rusfertide to treat PV (Pharmaceutical Technology)
Jan-05-26 07:00AM	Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) (Business Wire)
Dec-06-25 09:30AM	Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera (Business Wire)
Dec-05-25 04:21PM	Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory (Insider Monkey)
Nov-27-25 03:45AM	Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice (ACCESSWIRE)
Nov-06-25 05:45PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:42PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-04-25 10:00AM	Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-03-25 04:05PM	Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting (ACCESSWIRE)
Oct-30-25 10:00AM	Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 07:40AM	Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-27-25 07:35AM	Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences (ACCESSWIRE)
Oct-18-25 12:04PM	Johnson & Johnson's M&A Strategy Is the Real Story for Investors (MarketBeat)
Oct-13-25 02:50PM	Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal (Zacks) -9.00%
06:46AM	J&J in talks to acquire Protagonist Therapeutics (Pharmaceutical Technology)
Oct-10-25 07:07PM	Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today (Motley Fool) +29.77%
02:21PM	Trump's China tariff threat sinks stocks, Applied Digital surges (Yahoo Finance Video)
01:38PM	RTW Investments' Rod Wong: Expect more deals in biotech space (CNBC TV)
11:53AM	Protagonist Therapeutics stock surges after J&J acquisition talks report (Investing.com)
11:23AM	Protagonist Stock Surges on Johnson & Johnson Report (The Wall Street Journal)
11:13AM	Johnson & Johnson in Talks to Buy Protagonist Therapeutics (The Wall Street Journal)
10:23AM	Stock Market Today: Market Tumbles After Trump Threatens "Massive Increase" on China Tariffs (TheStreet)
Oct-07-25 08:10AM	Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill (ACCESSWIRE)
Sep-17-25 11:45AM	Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory (Insider Monkey)
08:00AM	Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress (ACCESSWIRE)
Sep-15-25 10:45AM	Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 (ACCESSWIRE)
Sep-12-25 11:36AM	JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
Sep-11-25 08:00AM	Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency (ACCESSWIRE)
Aug-26-25 04:05PM	Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 (ACCESSWIRE) +7.79%
Aug-25-25 07:00AM	Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera (ACCESSWIRE)
Aug-06-25 05:25PM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:24PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-22-25 11:51AM	JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
Jul-21-25 08:05AM	Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis (ACCESSWIRE)
Jun-30-25 04:09PM	Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? (Investor's Business Daily) -9.16%
04:05PM	Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity (ACCESSWIRE)
Jun-26-25 07:05AM	Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate (ACCESSWIRE)
Jun-24-25 03:09PM	Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera (Insider Monkey)
Jun-23-25 01:17PM	Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains? (Zacks)
09:07AM	Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? (Zacks)
Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com)
Jun-09-25 10:00AM	For Patients With Rare Blood Cancer, New Drug Offers Relief (The Wall Street Journal)
Jun-01-25 08:00AM	Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera (Business Wire)
May-27-25 09:29AM	Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome (Insider Monkey)
May-21-25 07:05AM	Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 (ACCESSWIRE)
May-12-25 08:11AM	J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study (Zacks) +5.35%
May-09-25 10:27AM	Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
08:05AM	Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting (ACCESSWIRE)
May-06-25 06:30PM	Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.13%
04:05PM	Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-23-25 10:35AM	Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 (ACCESSWIRE)
Apr-10-25 08:10AM	Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill (ACCESSWIRE)
Apr-01-25 02:27PM	Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns (Seeking Alpha)
Mar-25-25 09:55AM	Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? (Zacks)
Mar-18-25 02:10PM	Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) Best Biotech Stock for 2025? (Insider Monkey)
07:00AM	These 10 biotech companies are changing how we discover new drugs and treat complex diseases (FastCompany)
07:00AM	Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 (ACCESSWIRE)
Mar-15-25 04:40PM	Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? (Insider Monkey)
Mar-12-25 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why (Zacks)
Mar-11-25 09:29AM	Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success (GuruFocus.com) +6.81%
08:37AM	J&J and Protagonists icotrokinra scores in Phase IIb UC study (Clinical Trials Arena)
06:47AM	Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday (Insider Monkey)
Mar-10-25 04:30PM	Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out (Investor's Business Daily) +45.89%
08:15AM	Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis (ACCESSWIRE)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ali Asif	Chief Financial Officer	Sep 30 '26	Option Exercise	23.72	58,629	1,390,735	117,632	Oct 02 04:10 PM
Ali Asif	Chief Financial Officer	Sep 30 '26	Sale	141.78	58,629	8,312,294	59,003	Oct 02 04:10 PM
ASIF ALI	Officer	Sep 30 '26	Proposed Sale	140.97	58,629	8,264,930		Sep 30 04:20 PM
PATEL DINESH V PH D	President and CEO	Sep 09 '26	Option Exercise	21.58	63,548	1,371,366	586,516	Sep 10 09:17 PM
PATEL DINESH V PH D	President and CEO	Sep 08 '26	Option Exercise	21.58	54,174	1,169,075	577,142	Sep 10 09:17 PM
PATEL DINESH V PH D	President and CEO	Sep 10 '26	Option Exercise	21.58	7,278	157,059	530,246	Sep 10 09:17 PM
PATEL DINESH V PH D	President and CEO	Sep 09 '26	Sale	146.18	63,548	9,289,447	522,968	Sep 10 09:17 PM
PATEL DINESH V PH D	President and CEO	Sep 08 '26	Sale	145.87	54,174	7,902,361	522,968	Sep 10 09:17 PM
PATEL DINESH V PH D	President and CEO	Sep 10 '26	Sale	144.10	7,278	1,048,760	522,968	Sep 10 09:17 PM
PATEL DINESH V PH D	President and CEO	Aug 10 '26	Option Exercise	21.58	65,761	1,419,122	589,239	Aug 12 06:43 PM
PATEL DINESH V PH D	President and CEO	Aug 11 '26	Option Exercise	21.58	34,239	738,878	557,717	Aug 12 06:43 PM
PATEL DINESH V PH D	President and CEO	Aug 10 '26	Sale	149.11	65,761	9,805,623	523,478	Aug 12 06:43 PM
PATEL DINESH V PH D	President and CEO	Aug 11 '26	Sale	148.52	34,239	5,085,176	523,478	Aug 12 06:43 PM
Dinesh Patel	CEO	Aug 10 '26	Proposed Sale	149.26	225,000	33,583,500		Aug 10 04:49 PM
Waddill William D.	Director	Jun 23 '26	Option Exercise	16.54	9,000	148,860	16,825	Jun 25 04:10 PM
Waddill William D.	Director	Jun 23 '26	Sale	117.94	9,000	1,061,460	7,825	Jun 25 04:10 PM
WILLIAM WADDILL	Director	Jun 23 '26	Proposed Sale	115.03	9,000	1,035,270		Jun 23 04:27 PM
Waddill William D.	Director	Jun 10 '26	Option Exercise	14.96	9,000	134,640	16,825	Jun 11 07:06 PM
Waddill William D.	Director	Jun 10 '26	Sale	107.68	9,000	969,120	7,825	Jun 11 07:06 PM
WILLIAM WADDILL	Director	Jun 10 '26	Proposed Sale	105.87	9,000	952,830		Jun 10 04:29 PM
Waddill William D.	Director	May 29 '26	Option Exercise	11.80	9,000	106,200	16,825	Jun 01 06:31 PM
Waddill William D.	Director	May 29 '26	Sale	99.64	9,000	896,760	7,825	Jun 01 06:31 PM
WILLIAM WADDILL	Director	May 29 '26	Proposed Sale	100.41	9,000	903,690		May 29 04:23 PM
PATEL DINESH V PH D	President and CEO	May 12 '26	Option Exercise	21.58	75,000	1,618,500	598,478	May 12 07:28 PM
PATEL DINESH V PH D	President and CEO	May 12 '26	Sale	100.12	75,000	7,509,000	523,478	May 12 07:28 PM
Dinesh Patel	CEO	May 12 '26	Proposed Sale	103.50	75,000	7,762,500		May 12 05:29 PM
Giraudo Bryan	Director	May 07 '26	Option Exercise	6.63	36,000	238,560	43,825	May 11 08:25 PM
Giraudo Bryan	Director	May 07 '26	Sale	100.14	36,000	3,605,040	27,825	May 11 08:25 PM
Giraudo Bryan	Director	May 07 '26	Sale	100.07	12,000	1,200,840	6,000	May 11 08:25 PM
Giraudo Bryan	Director	May 08 '26	Sale	100.00	6,000	600,000	0	May 11 08:25 PM
Giraudo Bryan	Director	May 08 '26	Sale	100.00	5,130	513,000	12,695	May 11 08:25 PM
BRYAN M & COURTNEY L GIRAUDO	Director	May 08 '26	Proposed Sale	100.00	11,130	1,113,000		May 08 04:23 PM
BRYAN GIRAUDO	Director	May 07 '26	Proposed Sale	100.14	36,000	3,604,968		May 07 05:21 PM
BRYAN M & COURTNEY L GIRAUDO	Director	May 07 '26	Proposed Sale	100.07	12,000	1,200,874		May 07 04:49 PM
Ali Asif	Chief Financial Officer	Apr 20 '26	Sale	105.47	1,750	184,572	59,003	Apr 21 04:58 PM
Asif Ali	Officer	Apr 20 '26	Proposed Sale	105.47	1,750	184,572		Apr 21 04:57 PM
MOLINA ARTURO MD	Chief Medical Officer	Mar 26 '26	Option Exercise	8.04	15,000	120,600	99,115	Mar 27 07:36 PM
MOLINA ARTURO MD	Chief Medical Officer	Mar 26 '26	Sale	104.79	15,000	1,571,850	84,115	Mar 27 07:36 PM
SELICK HAROLD E	Director	Mar 26 '26	Option Exercise	12.88	24,000	309,120	84,845	Mar 27 07:34 PM
SELICK HAROLD E	Director	Mar 26 '26	Sale	105.00	24,000	2,520,000	60,845	Mar 27 07:34 PM
Ali Asif	Chief Financial Officer	Mar 26 '26	Option Exercise	17.70	24,765	438,280	85,518	Mar 27 07:33 PM
Ali Asif	Chief Financial Officer	Mar 26 '26	Sale	104.24	24,765	2,581,504	60,753	Mar 27 07:33 PM
HAROLD SELICK	Director	Mar 26 '26	Proposed Sale	105.00	24,000	2,520,000		Mar 26 04:05 PM
ASIF ALI	Officer	Mar 26 '26	Proposed Sale	104.24	24,765	2,581,546		Mar 26 04:05 PM
ARTURO MOLINA	Officer	Mar 26 '26	Proposed Sale	104.79	15,000	1,571,919		Mar 26 04:01 PM
PATEL DINESH V PH D	President and CEO	Mar 25 '26	Option Exercise	8.58	54,641	468,820	579,579	Mar 25 07:23 PM
PATEL DINESH V PH D	President and CEO	Mar 24 '26	Option Exercise	8.58	59	506	524,997	Mar 25 07:23 PM
PATEL DINESH V PH D	President and CEO	Mar 25 '26	Sale	101.00	54,641	5,518,741	524,938	Mar 25 07:23 PM
PATEL DINESH V PH D	President and CEO	Mar 24 '26	Sale	101.00	59	5,959	524,938	Mar 25 07:23 PM
Dinesh Patel	CEO	Mar 24 '26	Proposed Sale	98.54	54,700	5,390,138		Mar 24 05:56 PM
Williams Lewis T	Director	Feb 17 '26	Option Exercise	10.84	18,000	195,120	25,825	Feb 18 06:12 PM
Williams Lewis T	Director	Feb 17 '26	Sale	82.42	18,000	1,483,560	7,825	Feb 18 06:12 PM
LEWIS T WILLIAMS	Director	Feb 17 '26	Proposed Sale	82.42	18,000	1,483,495		Feb 17 05:27 PM
Waddill William D.	Director	Feb 06 '26	Option Exercise	8.31	20,000	166,200	27,825	Feb 06 04:38 PM
Waddill William D.	Director	Feb 06 '26	Sale	83.68	20,000	1,673,600	7,825	Feb 06 04:38 PM
WILLIAM D WADDILL	Director	Feb 06 '26	Proposed Sale	83.68	20,000	1,673,672		Feb 06 04:04 PM
PATEL DINESH V PH D	President and CEO	Jan 26 '26	Option Exercise	14.12	24,890	351,528	588,710	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 27 '26	Option Exercise	21.58	4,068	87,787	578,573	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 23 '26	Option Exercise	4.21	19,315	81,316	593,820	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 26 '26	Sale	84.03	24,890	2,091,470	574,505	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 23 '26	Sale	84.59	19,315	1,633,856	574,505	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 27 '26	Sale	83.19	4,068	338,417	574,505	Jan 27 09:21 PM
Ali Asif	Chief Financial Officer	Jan 27 '26	Option Exercise	16.18	28,000	453,080	106,523	Jan 27 09:20 PM
Ali Asif	Chief Financial Officer	Jan 27 '26	Sale	83.13	46,203	3,841,037	60,320	Jan 27 09:20 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 27 '26	Option Exercise	8.04	5,000	40,200	89,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 26 '26	Option Exercise	8.04	5,000	40,200	89,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 23 '26	Sale	82.42	13,151	1,083,905	84,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 26 '26	Sale	82.28	5,000	411,400	84,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 27 '26	Sale	82.00	5,000	410,000	84,115	Jan 27 09:19 PM
ASIF ALI	Officer	Jan 27 '26	Proposed Sale	83.14	46,203	3,841,128		Jan 27 05:12 PM
ARTURO MOLINA	Officer	Jan 27 '26	Proposed Sale	82.00	5,000	410,000		Jan 27 04:01 PM
ARTURO MOLINA	Officer	Jan 26 '26	Proposed Sale	82.28	5,000	411,396		Jan 26 04:29 PM
ARTURO MOLINA	Officer	Jan 23 '26	Proposed Sale	83.42	13,151	1,097,116		Jan 23 04:32 PM
Dinesh Patel	CEO	Jan 23 '26	Proposed Sale	84.62	108,273	9,162,061		Jan 23 04:06 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 20 '26	Sale	82.48	9,514	784,715	97,266	Jan 21 05:17 PM
PATEL DINESH V PH D	President and CEO	Jan 20 '26	Sale	82.48	34,438	2,840,446	580,505	Jan 21 05:16 PM
Ali Asif	Chief Financial Officer	Jan 20 '26	Sale	82.48	8,588	708,338	78,077	Jan 21 05:15 PM
ARTURO MOLINA MD	Officer	Jan 20 '26	Proposed Sale	82.48	9,514	784,715		Jan 21 05:12 PM
DINESH V PATEL PH D	Officer, Director	Jan 20 '26	Proposed Sale	82.48	34,438	2,840,446		Jan 21 05:11 PM
Asif Ali	Officer	Jan 20 '26	Proposed Sale	82.48	8,588	708,338		Jan 21 05:10 PM
SELICK HAROLD E	Director	Jan 09 '26	Option Exercise	4.21	14,299	60,199	60,845	Jan 13 04:45 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 17 '25	Sale	84.77	2,712	229,896	81,180	Nov 19 04:01 PM

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

CEODr. Dinesh V. Patel Ph.D.

Executive VP & CFOMr. Asif Ali

M.D.Dr. Arturo M. Molina FACP

EVP & Chief Technical OfficerMr. Venkat Thalladi Ph.D.

Executive VPDr. Newman Yeilding M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Protagonist Therapeutics Inc

Upgrade your Finviz experience